Celltrion Projected to Achieve First Annual Revenue of 5 Trillion Won (approx. $3.4 Billion) Driven by Expanding European Biosimilar Market Share

BigGo Finance South Korea

Overview

South Korean biopharmaceutical company Celltrion is projected to reach its first-ever annual revenue exceeding 5 trillion won (approximately $3.4 billion) in 2026, buoyed by robust performance in the European autoimmune disease treatment market. Its flagship Remsima product line, including the subcutaneous RemsimaSC, commanded a combined 70% share of the European infliximab market by Q4 2025, with RemsimaSC alone capturing over 50% in Germany. New high-margin biosimilars Omlyclo and Aptozma are rapidly gaining traction, highlighting Celltrion’s strong European presence and successful high-value biosimilar strategy.

In Depth

Background

The global biosimilar market is experiencing rapid expansion, driven by the expiry of patents for key biological drugs. The market for autoimmune disease treatments, in particular, presents significant opportunities for biosimilars due to substantial unmet medical needs and the high cost of originator drugs. South Korea’s Celltrion has long focused on the development and manufacturing of biosimilars, establishing a strong presence in the European market. By balancing cost-effectiveness with high quality, the company aims to improve patient access while contributing to healthcare cost reduction.

Key Findings / Results

Celltrion, a South Korean biopharmaceutical company, is projected to achieve a landmark milestone in 2026, with its annual revenue expected to surpass 5 trillion won (approximately $3.4 billion) for the first time. This impressive growth is primarily fueled by the company’s strong performance in the European market for autoimmune disease treatments. Celltrion’s flagship Remsima product line, especially the subcutaneous formulation RemsimaSC, has dominated the market due to its convenience and efficacy. By Q4 2025, the Remsima portfolio collectively held an overwhelming 70% share of the European infliximab market, with RemsimaSC alone capturing over 50% market share in Germany.

Furthermore, new high-margin biosimilar products, Omlyclo and Aptozma, are also gaining rapid market acceptance. Omlyclo achieved a 15% European market share within two quarters of its launch, and Aptozma secured a 5% share shortly after its sequential rollout. Celltrion reported a consolidated revenue of 1.15 trillion won and an operating profit of 321.9 billion won for Q1 2026, marking substantial year-over-year increases of 36% and 115.5%, respectively. This growth is anticipated to accelerate further in the second half of the year, as European pharmaceutical tenders typically occur in Q2 and Q3. The company’s strategy is centered on expanding market share for these high-margin biosimilars and leveraging its robust existing presence in Europe.

Technical Significance & Outlook

Celltrion’s success clearly demonstrates that high-quality biosimilars are being embraced by both healthcare systems and patients as cost-effective alternatives to originator drugs. The significant market success of improved formulations like RemsimaSC, in particular, highlights the profound impact of drug delivery system (DDS) innovations on biosimilar market competitiveness. The company’s strong financial foundation and leadership in the European market are expected to further accelerate the development and introduction of future novel biosimilars. Moreover, Celltrion’s achievements serve as a crucial example that the South Korean biopharmaceutical industry can compete effectively in the global market. Moving forward, the company is expected to sustain its growth by expanding its portfolio of high-value novel biosimilars and implementing optimized regional market strategies.